We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IEX:NYSEIDEX Corporation Analysis

Data as of 2026-09-09 - not real-time

$225.10

Latest Price

3/10Risk

Risk Level: Low

Executive Summary

The moving-average structure behind IDEX Corporation is bullish at $225.10, with short-term averages leading the long-term ones. With RSI at 42.4 the momentum picture is neutral, alongside a bearish MACD signal. The recent range runs from support at $220.98 up to resistance at $242.73.
Multiples put this in fair territory: 32.4 times earnings against the sector's 27.9. Sell-side targets cluster 13.5% above the current quote. Revenue is growing at 6.4% on a 14.5% profit margin. The 1.29% dividend yield looks covered by current payout levels.
The composite risk read is 3/10, putting it in low territory. With 30-day volatility of 20.6%, a beta of 0.69 and a maximum drawdown of 14.5%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 2 out of 10.

Top Market Events

IDEX Corporation recently reported its second-quarter 2026 results, with sales rising to US$920.Manufacturing company IDEX NYSE:IEX reported in Q2 CY2026, with sales up 6.Manufacturing company IDEX NYSE:IEX reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 206.54
  • MACD momentum is negative

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • P/E of 32.4 versus sector average of 27.9
  • Trading above the 200-day average of 206.54

Long Term

> 3 years
Neutral
Model confidence: 2/10

Key Factors

  • P/E of 32.4 versus sector average of 27.9
  • Analyst targets imply +13.5% versus the current price
  • Dividend yield of 1.29%

Key Metrics & Analysis

Financial Health

Revenue Growth6.40%
Profit Margin14.49%
P/E Ratio32.4
ROE12.96%
ROA6.84%
Debt/Equity47.06
P/B Ratio4.2
Op. Cash Flow$716.7M
Free Cash Flow$555.6M
Industry P/E27.9

Technical Analysis

TrendBullish
RSI42.4
Support$220.98
Resistance$242.73
MA 20$231.63
MA 50$228.71
MA 200$206.54
MACDBearish
VolumeDecreasing
Fear & Greed Index92.04

Valuation

Fair Value$107.60
Target Price$255.57
Upside/Downside13.54%
GradeFair
TypeGrowth
Dividend Yield1.29%

Risk Assessment

Beta0.69
Volatility20.57%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.